NAGE vs YDES
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
NAGE demonstrates strong operational health with a Piotroski F-Score of 7/9 and a pristine balance sheet characterized by a very low Debt/Equity ratio (0.04). However, the stock is trading at a significant premium to its Graham Number ($2.08) and Intrinsic Value ($1.40), suggesting a valuation disconnect. While the company has successfully transitioned from historical losses to profitability—a rarity in the biotech sector—recent YoY earnings growth has plummeted by 41.6%. The conflict between a 'Strong Buy' analyst consensus and a completely bearish technical trend (0/100) warrants a cautious approach.
YDES exhibits severe financial instability characterized by a weak Piotroski F-Score of 3/9 and a catastrophic technical trend. While the company maintains a pristine balance sheet with zero debt and an exceptional current ratio of 13.18, these are offset by an absurd Price-to-Sales ratio of 724.75 and deeply negative operating margins (-444.59%). The stock is currently in a freefall, trading near its 52-week low after a 60.7% one-year decline, suggesting a massive loss of investor confidence despite high year-over-year revenue growth.
Compare Another Pair
Related Comparisons
NAGE vs YDES: Head-to-Head Comparison
This page compares Niagen Bioscience, Inc. (NAGE) and YD Bio Ltd (YDES) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.